KR20070090941A - 트리아졸론, 테트라졸론 및 이미다졸론 유도체의 알파-2ｃ아드레날린수용체 길항제로의 용도 - Google Patents

트리아졸론, 테트라졸론 및 이미다졸론 유도체의 알파-2ｃ아드레날린수용체 길항제로의 용도 Download PDF

Info

Publication number
KR20070090941A
KR20070090941A KR1020077014061A KR20077014061A KR20070090941A KR 20070090941 A KR20070090941 A KR 20070090941A KR 1020077014061 A KR1020077014061 A KR 1020077014061A KR 20077014061 A KR20077014061 A KR 20077014061A KR 20070090941 A KR20070090941 A KR 20070090941A
Authority
KR
South Korea
Prior art keywords
compound
group
mol
alkyl
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077014061A
Other languages
English (en)
Korean (ko)
Inventor
조세 이그나시오 안드레스-길
마누엘 제수스 알카자르-바카
조아퀸 파스토르-페르난데즈
빌헬무스 헬레나 이그나티우스 마리아 드린켄부르그
자비어 진 미셀 란글로이스
줄렌 오이아르자발-산타마리나
주안 안토니오 베가-라미로
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20070090941A publication Critical patent/KR20070090941A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077014061A 2004-12-21 2005-12-20 트리아졸론, 테트라졸론 및 이미다졸론 유도체의 알파-2ｃ아드레날린수용체 길항제로의 용도 Withdrawn KR20070090941A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04106817.2 2004-12-21
EP04106817 2004-12-21
EP05104873 2005-06-03
EP05104873.4 2005-06-03

Publications (1)

Publication Number Publication Date
KR20070090941A true KR20070090941A (ko) 2007-09-06

Family

ID=36013649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077014061A Withdrawn KR20070090941A (ko) 2004-12-21 2005-12-20 트리아졸론, 테트라졸론 및 이미다졸론 유도체의 알파-2ｃ아드레날린수용체 길항제로의 용도

Country Status (15)

Country Link
US (1) US20100029620A1 (https=)
EP (1) EP1831185A1 (https=)
JP (1) JP2008524312A (https=)
KR (1) KR20070090941A (https=)
AR (1) AR052342A1 (https=)
AU (1) AU2005318188A1 (https=)
BR (1) BRPI0516380A (https=)
CA (1) CA2588028A1 (https=)
EA (1) EA011514B1 (https=)
IL (1) IL184048A0 (https=)
MX (1) MX2007007472A (https=)
NO (1) NO20073760L (https=)
PA (1) PA8657301A1 (https=)
TW (1) TW200635906A (https=)
WO (1) WO2006067139A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
MX2013003633A (es) * 2010-10-01 2013-04-24 Taisho Pharmaceutical Co Ltd Derivado de 1, 2, 4-triazolona.
FR2976287B1 (fr) 2011-06-09 2013-07-05 Pf Medicament Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique
PL2772482T3 (pl) * 2011-10-27 2016-08-31 Taisho Pharmaceutical Co Ltd Pochodna azolu
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
BR112015030824A2 (pt) * 2013-06-11 2017-07-25 Hoffmann La Roche novos derivados de tetrazolona
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
CN109476646A (zh) 2016-07-12 2019-03-15 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
CA3185336A1 (en) * 2017-11-06 2019-05-09 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
JP2021183586A (ja) * 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3355457A (en) * 1965-05-21 1967-11-28 American Cyanamid Co Substituted 2-imidazolinones
DE2725148A1 (de) * 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
SG48386A1 (en) * 1994-01-24 1998-04-17 Janssen Pharmaceutica Nv Watersoluble azole antifungals
JPH0899975A (ja) * 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JPH09183770A (ja) * 1995-10-31 1997-07-15 Nippon Bayeragrochem Kk １−アジン−テトラゾリノン類及び除草剤
WO1998025912A1 (en) * 1996-12-13 1998-06-18 E.I. Du Pont De Nemours And Company Herbicidal heterocyclic amides
WO1998051683A1 (en) * 1997-05-15 1998-11-19 E.I. Du Pont De Nemours And Company Herbicidal tetrazolinones
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
JP3837242B2 (ja) * 1998-08-25 2006-10-25 北興化学工業株式会社 トリアゾリノン誘導体および除草剤
WO2000010984A1 (en) * 1998-08-19 2000-03-02 Hokko Chemical Industry Co., Ltd. Triazolinone derivatives and herbicide compositions

Also Published As

Publication number Publication date
AR052342A1 (es) 2007-03-14
WO2006067139A1 (en) 2006-06-29
IL184048A0 (en) 2007-10-31
AU2005318188A1 (en) 2006-06-29
EA200701345A1 (ru) 2007-10-26
PA8657301A1 (es) 2007-01-17
EA011514B1 (ru) 2009-04-28
US20100029620A1 (en) 2010-02-04
NO20073760L (no) 2007-07-19
TW200635906A (en) 2006-10-16
EP1831185A1 (en) 2007-09-12
CA2588028A1 (en) 2006-06-29
BRPI0516380A (pt) 2008-09-02
JP2008524312A (ja) 2008-07-10
MX2007007472A (es) 2007-07-20

Similar Documents

Publication Publication Date Title
EP2205594B1 (en) 1,3,5-trisubstituted triazole derivative
EP2491024B1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
PL187769B1 (pl) Pochodna 2,4-diaminopirymidyny jako antagonista receptora dopaminergicznego D, kompozycja farmaceutyczna, sposób wytwarzania kompozycji farmaceutycznej, zastosowanie pochodnej 2,4-diaminopirymidyny,sposób wytwarzania pochodnej 2,4 diaminopirymidyny
JP5841617B2 (ja) アルファ７ｎＡＣｈＲのアロステリック調節因子としての（ピリジン−４−イル）ベンジルアミド
EP2148873B1 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
JP2009537602A (ja) 薬剤として用いるための置換ピラジノン誘導体
JP2010505908A (ja) 薬剤として用いるための置換ピラジノン誘導体
KR20070090941A (ko) 트리아졸론, 테트라졸론 및 이미다졸론 유도체의 알파-2ｃ아드레날린수용체 길항제로의 용도
EP2148879B1 (en) Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
IL199076A (en) Piperidinylamino-pyridazines and their use as dopamine receptor 2 antagonists that break down rapidly
AU2008240727A1 (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
KR20080109789A (ko) 의약품으로 사용하기 위한 치환된 피라지논 유도체
SK278557B6 (en) Piperidylmethyl substituted derivatives of chroman, producing method and use thereof, and pharmaceutical composition containing same
CN101084225B (zh) 具有改良的抗精神病和抗焦虑活性的异噁唑啉-吲哚衍生物
EP1966191B1 (en) Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070621

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid